FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Onconetix, Inc. Stock AnalysisComprehensive stock analysis for Onconetix, Inc. (ONCO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisONCO
ONCO
Onconetix, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ONCO
Home🔹Stocks🔹Onconetix, Inc.

Onconetix, Inc.

ONCO•NASDAQ

Onconetix, Inc.

ONCO•NASDAQ
Market cap
$277.28K
Sentiment

Your view on ONCO

Mkt Cap
$277.28K
Sentiment
Your view
ONCO
Onconetix, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ONCO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Onconetix, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Karina Fedasz
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Karina Fedasz
Headquarters
US
Description

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News